Dupilumab and tralokinumab are currently the only FDA-approved biologic therapies for the treatment of moderate-to-severe atopic dermatitis. Tralokinumab is approved for patients greater than 18 years old, and dupilumab is approved for patients as young as 6 months old. Both medications are effective in clinical trials at improving atopic dermatitis. With a good safety profile and low-risk adverse events, dupilumab and tralokinumab are generally excellent treatment options for patients with severe or refractory atopic dermatitis.
Keywords: Adverse effects; Atopic dermatitis; Biologics; Clinic trial; Dupilumab; IL-4 receptor inhibition; Immunomodulators; Pharmacokinetics; Tralokinumab; Biologic agents.
© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.